Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Stocks in this Quantisnow insightHealth Care
Historical context for NAGE
Across the 20 sessions after earlier NAGE headlines, the stock closed higher 8 times and lower 11 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NAGE | SPY |
|---|---|---|---|
| May 8, 2026 | Niagen Bioscience Announces Participation in Upcoming Investor Conferences | -0.5% | +0.8% |
| May 7, 2026 | Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results | -15.7% | -0.3% |
| May 4, 2026 | Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering | +1.6% | -0.4% |
| Apr 28, 2026 | Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™ | -2.4% | -0.5% |
| Apr 22, 2026 | Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | +5.9% | +1.0% |
| Apr 9, 2026 | Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen® | -2.6% | +0.6% |
Keep researching NAGE
- NAGE insider tradesEvery buy and sale reported by Niagen Bioscience Inc. officers, directors and large holders.
- NAGE earnings historyPast Niagen Bioscience Inc. earnings releases, newest first.
- NAGE financial statementsRevenue, profit, cash flow and balance sheet from Niagen Bioscience Inc.'s SEC filings.
Quantisnow market dataNASDAQ
NAGE
Niagen Bioscience Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
Get push alerts for NAGE
Full NAGE profile on Quantisnow Follow NAGE and get a push notification the moment its next story breaks.